CD14 Contributes to Warm Hepatic Ischemia-Reperfusion Injury in Mice

ABSTRACT Introduction: Ischemia/reperfusion (I/R) of the liver contributes to the pathobiology of liver injury in transplantation, liver surgery, and hemorrhagic shock. Ischemia/reperfusion induces an inflammatory response that is driven, in part, by Toll-like receptor 4 (TLR) signaling. CD14 is known to participate in the function of TLR4. We hypothesized that CD14 would be involved in the pathobiology of warm hepatic I/R. Methods: Using a 70% liver inflow inclusion model, CD14 knockout and wild-type (WT) mice were subjected to 1-h warm ischemia followed by reperfusion. CD14 mRNA, circulating transaminase, interleukin 6, soluble CD14, and high-mobility group box 1 (HMGB1) levels were measured. CD14 neutralizing antibody or isotype control antibody was given before ischemia or reperfusion for CD14 blockade in WT mice. Recombinant HMGB1 was given before reperfusion in some experiments to test if liver injury worsens. Results: There was an upregulation of CD14 mRNA in reperfused livers together with increased soluble CD14 levels in the circulation. Compared with WT control mice, CD14 knockout mice had much lower alanine aminotransferase and interleukin 6 levels at 6 and 24 h following I/R, and much less liver necrosis by histology. TUNEL (terminal deoxynucleotidyl-transferase dUTP nick end labeling) staining displayed less apoptosis at 24 h in the absence of CD14. CD14 blockage by neutralizing antibody also attenuated liver injury and the inflammatory response in C57BL/6 mice following I/R, but did not provide additional protection to TLR4 mutant C3H/Hej mice. CD14 deficiency did not change circulating HMGB1 levels following I/R (6 h). A dose of recombinant HMGB1, which worsened hepatic injury when given before reperfusion in WT mice, did not increase liver damage in CD14-deficient mice. Conclusions: CD14 is actively involved in hepatic I/R injury. Its deficiency or blockade ischemia attenuates liver injury and inflammatory response. CD14 mediates liver damage and inflammatory responses in the setting of warm hepatic I/R in mice.

[1]  M. Lotze,et al.  Signaling of High Mobility Group Box 1 (HMGB1) through Toll-like Receptor 4 in Macrophages Requires CD14 , 2013, Molecular Medicine.

[2]  M. Li,et al.  The role of CD14 and Toll-like receptor 4 of Kupffer cells in hepatic ischemia-reperfusion injury in rats. , 2012, Transplantation proceedings.

[3]  F. Granucci,et al.  CD14 Controls the LPS-Induced Endocytosis of Toll-like Receptor 4 , 2011, Cell.

[4]  T. Poll,et al.  Role of CD14 in lung inflammation and infection , 2010, Critical Care.

[5]  Haichao Wang,et al.  NOVEL HMGB1-INHIBITING THERAPEUTIC AGENTS FOR EXPERIMENTAL SEPSIS , 2009, Shock.

[6]  T. Billiar,et al.  Mechanisms of Toll-Like Receptor 4 (TLR4)-Mediated Inflammation After Cold Ischemia/Reperfusion in the Heart , 2009, Transplantation.

[7]  T. Billiar,et al.  β2-Integrin-induced p38 MAPK Activation Is a Key Mediator in the CD14/TLR4/MD2-dependent Uptake of Lipopolysaccharide by Hepatocytes* , 2008, Journal of Biological Chemistry.

[8]  Jeon-Soo Shin,et al.  High Mobility Group Box 1 Protein Binding to Lipopolysaccharide Facilitates Transfer of Lipopolysaccharide to CD14 and Enhances Lipopolysaccharide-Mediated TNF-α Production in Human Monocytes1 , 2008, The Journal of Immunology.

[9]  C. Steinem,et al.  Hsp70 Translocates into the Plasma Membrane after Stress and Is Released into the Extracellular Environment in a Membrane-Associated Form that Activates Macrophages1 , 2008, The Journal of Immunology.

[10]  F. Gao,et al.  Absence of toll‐like receptor 4 (TLR4) signaling in the donor organ reduces ischemia and reperfusion injury in a murine liver transplantation model , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  P. Tobias,et al.  Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. , 2006, Immunity.

[12]  K. Tracey,et al.  The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion , 2005, The Journal of experimental medicine.

[13]  Ryan M. O’Connell,et al.  Cutting Edge: TLR4 Activation Mediates Liver Ischemia/Reperfusion Inflammatory Response via IFN Regulatory Factor 3-Dependent MyD88-Independent Pathway1 , 2004, The Journal of Immunology.

[14]  N. Weintraub,et al.  Regulation of Endotoxin-Induced Proinflammatory Activation in Human Coronary Artery Cells: Expression of Functional Membrane-Bound CD14 by Human Coronary Artery Smooth Muscle Cells1 , 2004, The Journal of Immunology.

[15]  Hui Wang,et al.  Toll-like receptor 4 involvement in hepatic ischemia/reperfusion injury in mice. , 2004, Hepatobiliary & pancreatic diseases international : HBPD INT.

[16]  C. Gabay,et al.  CD14 Is an Acute-Phase Protein1 , 2004, The Journal of Immunology.

[17]  U. Göbel,et al.  Lipoteichoic Acid (LTA) of Streptococcus pneumoniaeand Staphylococcus aureus Activates Immune Cells via Toll-like Receptor (TLR)-2, Lipopolysaccharide-binding Protein (LBP), and CD14, whereas TLR-4 and MD-2 Are Not Involved* , 2003, The Journal of Biological Chemistry.

[18]  T. Calandra,et al.  Critical Role of Lipopolysaccharide-Binding Protein and CD14 in Immune Responses against Gram-Negative Bacteria1 , 2001, The Journal of Immunology.

[19]  I. Moro,et al.  CD14 Is Expressed and Released as Soluble CD14 by Human Intestinal Epithelial Cells In Vitro: Lipopolysaccharide Activation of Epithelial Cells Revisited , 2001, Infection and Immunity.

[20]  G. Hodge,et al.  Synthesis and Surface Expression of CD14 by Human Endothelial Cells , 2001, Infection and Immunity.

[21]  Dong-er Zhang,et al.  Hepatocytes Contribute to Soluble CD14 Production, and CD14 Expression Is Differentially Regulated in Hepatocytes and Monocytes* , 2000, The Journal of Biological Chemistry.

[22]  Stuart K. Calderwood,et al.  HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine , 2000, Nature Medicine.

[23]  R. Ulevitch,et al.  Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Clemens,et al.  REMODELING OF HEPATIC MICROVASCULAR RESPONSIVENESS AFTER ISCHEMIA/REPERFUSION , 1997, Shock.

[25]  R. Ulevitch,et al.  Antibodies against CD14 protect primates from endotoxin-induced shock. , 1996, The Journal of clinical investigation.

[26]  J. Silver,et al.  Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. , 1996, Immunity.

[27]  C. Eckerskorn,et al.  Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfectants , 1995, European journal of immunology.

[28]  R. Ulevitch,et al.  Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Poll,et al.  Role of CD14 in Lung Inflammation and Infection , 2011, Intensive Care Medicine.

[30]  W. Zong,et al.  Necrotic death as a cell fate. , 2006, Genes & development.

[31]  Samuel I. Miller,et al.  LPS, TLR4 and infectious disease diversity , 2005, Nature Reviews Microbiology.